Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective.
Objective: The PAOLA-1 trial demonstrated that olaparib plus bevacizumab (OB) significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to bevacizumab monotherapy (BM) as first-line maintenance therapy for patients with advanced ovarian cancer (AOC) who had homologou...
| Publicado en: | DARU: Journal of Pharmaceutical Sciences Vol. 34; no. 2; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
7/22/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195542257&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195542257 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15608115 8WS jtl: DARU: Journal of Pharmaceutical Sciences issn: 15608115 maglogo: N pubinfo: dt: 7/22/2026 vid: 34 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 195542257 195542257 195542257 10.1007/s40199-026-00621-1 195542257 ppf: 1 ppct: 13 formats: tig: atl: Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective. aug: au: Cai, Pengxiang Liu, Jin Yu, Caifen Chen, Qing Huang, Shan Zeng, Lingjun Sun, Yong Huang, Aiwen affil: https://ror.org/05n0qbd70 Fuzong Teaching Hospital of Fujian University of Traditional Chinese Medicine, 900th Hospital of the Joint Logistics Support Force, Fuzhou, China sug: subj: Cost Benefit Analysis Bevacizumab Therapeutic Use Poly(ADP-Ribose) Polymerase Inhibitors Therapeutic Use Ovarian Neoplasms Drug Therapy Ovarian Neoplasms Economics Disease Progression Risk Factors Risk Assessment Health Systems Agencies China Human China Female Middle Age Secondary Analysis Descriptive Statistics Kaplan-Meier Estimator Parametric Statistics Post Hoc Analysis Overall Survival Progression-Free Survival Hidden Markov Models Quality-Adjusted Life Years Breast Neoplasms Disease Susceptibility Genes, BRCA Mutation Middle Aged: 45-64 years Female ab: Objective: The PAOLA-1 trial demonstrated that olaparib plus bevacizumab (OB) significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to bevacizumab monotherapy (BM) as first-line maintenance therapy for patients with advanced ovarian cancer (AOC) who had homologous recombination deficiency (HRD)-positive status at high risk of disease progression (HRisk-HRD+), including both the breast cancer susceptibility gene mutated (BRCAm) subgroup and the BRCA wild-type (BRCAwt) subgroup. This study aimed to assess its cost-effectiveness from the perspective of the Chinese healthcare system. Methods: A state-transition Markov model over a 20-year lifetime horizon was developed to evaluate the cost-effectiveness of OB compared to BM. The willingness-to-pay (WTP) thresholds were set at 1 to 3 times the gross domestic product per capita of China in 2024 ($13444.68 to $40334.05/QALY). The primary outcomes included total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Subgroup analysis, sensitivity analysis and scenario analyses were performed to validate the robustness of the study. Results: Compared with BM, the ICERs of OB were $10806.70/QALY, $10478.80/QALY and $25114.44/QALY in the HRisk-HRD+ population, BRCAm subgroup and BRCAwt subgroup, respectively. OB demonstrated potential cost-effectiveness for patients with HRisk-HRD+ AOC, particularly those with a BRCA mutation. One-way sensitivity analysis indicated that the discount rate and the price of olaparib were the primary factors influencing the ICER. The results of the probabilistic sensitivity analysis and scenario analysis were generally consistent with those of the base-case analysis. Conclusions: Compared to BM, OB demonstrated superior cost-effectiveness as first-line maintenance therapy for patients with HRisk-HRD+ AOC, particularly those with a BRCA mutation in China. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|